These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21425240)

  • 1. Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.
    Micheli F
    ChemMedChem; 2011 Jul; 6(7):1152-62. PubMed ID: 21425240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.
    Micheli F; Arista L; Bertani B; Braggio S; Capelli AM; Cremonesi S; Di-Fabio R; Gelardi G; Gentile G; Marchioro C; Pasquarello A; Provera S; Tedesco G; Tarsi L; Terreni S; Worby A; Heidbreder C
    J Med Chem; 2010 Oct; 53(19):7129-39. PubMed ID: 20839775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.
    Micheli F; Andreotti D; Braggio S; Checchia A
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4566-8. PubMed ID: 20573506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D3 receptor antagonists as therapeutic agents.
    Joyce JN; Millan MJ
    Drug Discov Today; 2005 Jul; 10(13):917-25. PubMed ID: 15993811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [3-azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonists.
    Micheli F; Hamprecht D; Bonanomi G; Di Fabio R; Donati D; Gentile G; Heidbreder C; Prandi A; Tarsi L; Terreni S
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5491-4. PubMed ID: 20692836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization.
    Micheli F; Holmes I; Arista L; Bonanomi G; Braggio S; Cardullo F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Terreni S; Heidbreder C; Savoia C; Griffante C; Worby A
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4011-3. PubMed ID: 19553113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.
    Micheli F; Arista L; Bonanomi G; Blaney FE; Braggio S; Capelli AM; Checchia A; Damiani F; Di-Fabio R; Fontana S; Gentile G; Griffante C; Hamprecht D; Marchioro C; Mugnaini M; Piner J; Ratti E; Tedesco G; Tarsi L; Terreni S; Worby A; Ashby CR; Heidbreder C
    J Med Chem; 2010 Jan; 53(1):374-91. PubMed ID: 19891474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.
    Jardemark K; Wadenberg ML; Grillner P; Svensson TH
    Curr Opin Investig Drugs; 2002 Jan; 3(1):101-5. PubMed ID: 12054059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective dopamine D3 receptor antagonists: a review 2001-2005.
    Micheli F; Heidbreder C
    Recent Pat CNS Drug Discov; 2006 Nov; 1(3):271-88. PubMed ID: 18221209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D3 receptor antagonists: a patent review (2007 - 2012).
    Micheli F; Heidbreder C
    Expert Opin Ther Pat; 2013 Mar; 23(3):363-81. PubMed ID: 23282131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.
    Geneste H; Amberg W; Backfisch G; Beyerbach A; Braje WM; Delzer J; Haupt A; Hutchins CW; King LL; Sauer DR; Unger L; Wernet W
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1934-7. PubMed ID: 16439127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.
    Micheli F; Bonanomi G; Braggio S; Capelli AM; Celestini P; Damiani F; Di Fabio R; Donati D; Gagliardi S; Gentile G; Hamprecht D; Petrone M; Radaelli S; Tedesco G; Terreni S; Worby A; Heidbreder C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):901-7. PubMed ID: 18248991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D3 receptor ligands with antagonist properties.
    Hackling AE; Stark H
    Chembiochem; 2002 Oct; 3(10):946-61. PubMed ID: 12362359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel, Selective, and Developable Dopamine D
    Micheli F
    ChemMedChem; 2017 Aug; 12(16):1254-1260. PubMed ID: 28426179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.
    Micheli F; Bonanomi G; Braggio S; Capelli AM; Damiani F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Perini O; Petrone M; Tedesco G; Terreni S; Worby A; Heidbreder C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):908-12. PubMed ID: 18178090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
    Heidbreder C
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.
    Heidbreder CA; Newman AH
    Ann N Y Acad Sci; 2010 Feb; 1187():4-34. PubMed ID: 20201845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.